Composition Perkirol ® 0.25 Tablet: Each film coated tablet contains ...

In clinical trials of patients being treated for RPerkirol ® can be discontinued without a tapeContraindication and precautionThis is contraindicated for patients known toDue to the pharmacological action of Ropinirdisease should be treated with caution.Co-administration of Ropinirole with anti-hypnot been studied. As with other dopaminergicthese compounds are given concomitantly witpotential for the occurrence of hypotension, b

Ropinirole is associated with somnolence andexcessive daytime somnolence and sudden sleDrug InteractionNeuroleptics and other centrally acting dopammetoclopramide, may diminish the effectivenconcomitant use of these drugs with RopiniroNo phramcokinetic interaction has been seenDomperidone which would necessitate dosagehas been seen between Ropinirole and other dDisease but, as is common practive, care shoutreatment regimen. Other dopamine agonists mIt has been establish from in vitro experimentcytochrome P450 enzyme CYP1A2. There is,between Ropinirole and substrates (such as thciprofloxacin, fluvoxamine and cimetidine) oRopinirole, the dose of Ropinirole may need tintroduced or withdrawn.Increased plasma concentrations of Ropinirolwith high doses of oestrogens. In patients alre